Sugi Predict

Sugi Predict / Compounds / SCHEMBL288849

SCHEMBL288849

SCHEMBL288849

O=C(O)C1CCC(=O)N1Cc1cccc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 8/20 0.58
▸ TP53 P04637 1/20 0.53
▸ MDM2 Q00987 1/20 0.53
▸ GYS1 P13807 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ USP2 O75604 1/20 0.48
▸ SIGMAR1 Q99720 1/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612852 1.00 P2RX7 (0.58) P2RX7TP53MDM2GYS1CYP1A2
SCHEMBL30061816 1.00 P2RX7 (0.58) P2RX7TP53MDM2GYS1CYP1A2
SCHEMBL2448764 1.00 P2RX7 (0.58) P2RX7TP53MDM2GYS1CYP1A2
SCHEMBL28021326 0.91 P2RX7 (0.57) P2RX7TP53MDM2CYP1A2CYP3A4
SCHEMBL19974972 0.90 P2RX7 (0.56) P2RX7TP53MDM2CYP1A2CYP3A4
SCHEMBL16328230 0.88 P2RX7 (0.60) P2RX7TP53MDM2CYP1A2CYP3A4
SCHEMBL288651 0.87 P2RX7 (0.56) P2RX7GYS1CYP3A4CYP2D6CYP2C9
SCHEMBL289574 0.87 P2RX7 (0.56) P2RX7GYS1CYP3A4CYP2D6CYP2C9
SCHEMBL288652 0.87 P2RX7 (0.56) P2RX7GYS1CYP3A4CYP2D6CYP2C9
SCHEMBL10377790 0.86 P2RX7 (0.60) P2RX7TP53MDM2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 — — US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 — — US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 — — US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 — — CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 — — US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 — — US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 — — EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 — — WO disclosed
EP-2427429-B1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBVIE DEUTSCHLAND (DE) 2017-02-15 — — EP disclosed
US-9527811-B2 Carboxamide compounds and their use as calpain inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2016-12-27 — — US disclosed
EP-2364984-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 — — EP disclosed
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2011-04-14 — — US disclosed
WO-2010128102-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 — — WO disclosed
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 — — US disclosed
EP-0197318-B1 Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1990-05-09 — — EP disclosed
US-4742171-A AROMATIZATION, REARRANGEMENT HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-05-03 — — US disclosed
US-4742061-A Benzoc[c]-1,5-naphthyridines and related compounds as memory enhancing agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-05-03 — — US disclosed
US-4670562-A MEMORY ENHANCEMENT HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-06-02 — — US disclosed
US-4652567-A Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-03-24 — — US disclosed
EP-0197318-A1 Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1986-10-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885TP53 3256/4885MDM2 3336/4885
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 P2RX7 1852/4885TP53 3609/4885MDM2 1661/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C P2RX7 564/4885TP53 3198/4885MDM2 3541/4885
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 P2RX7 1852/4885TP53 3609/4885MDM2 1661/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885TP53 3256/4885MDM2 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.